Hoth Therapeutics, Inc.(HOTH) Tuesday reported positive interim data from its Phase 2a study dubbed CLEER-001, evaluating HT-001 for the treatment of pruritus associated with skin toxicities caused by Epidermal Growth Factor Receptor (EGFR) inhibitors.
EGFR inhibitors, widely used in oncology, commonly cause skin-related adverse effects, including intense itching.
In the CLEER-001 study, patients experienced a 50 percent reduction in pruritus severity, with mean scores dropping from 1.6 on Day 1 to 0.8 by Day 21. Rapid symptom relief was also observed, with mean scores improving to 1.0 by Day 7. Some patients achieved complete resolution of pruritus within the 21-day period. Further, HT-001 was well tolerated, and no treatment-related serious adverse events were reported.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.